Digital Medicare advisor Chapter received $ 42 million in an Addition-led Series B funding round that included Narya Capital, Susa Ventures, Maverick Ventures, XYZ Venture Capital, Core Innovation Capital, and Health2047 Capital Partners.
The company is able to help employers work with their employees to transition their plans to Medicare. Patients can use the platform to navigate the Medicare system.
To date, the company has a total of $ 61 million in funding.
Clinical prediction software company Quris raised $ 28 million in a Welltech Ventures-led seed funding round involving iAngels and GlenRock Capital.
The new funds are intended to help expand the team and advance research and development of new drugs. The tool’s clinical AI prediction platform is currently working with partners on drug development for Fragile X Syndrome (FXS).
“Now is the time to use technology to transform drug development and end the costly cycle of failed clinical trials,” said Isaac Bentwich, CEO of Quris, in a statement. “The additional support from investors will help Quris grow the team and partnerships required to provide a clear vision of predicting the clinical safety of drugs for individual patients. With the technological advances available to us, we can close the clinical prediction gap. “
Digital healthcare company focused on motherhood Diana Health raised $ 11 million in a Series A financing round led by LRVHealth and .406 Ventures, including AlleyCorp. The new funds will be used to help the start-up open its first location.
The company works with hospitals to provide patients and doctors with digital resources with technology-enabled services to personalize the pregnancy journey.
“The care we receive as women, particularly during pregnancy and childbirth, has the potential to impact population health across generations while building lifelong connections between a family and their health care provider,” said Kate Condliffe, Co-Founder and CEO of Diana Health, in a statement.
“Traditional care models can make it difficult for providers to take advantage of this opportunity. For this reason, we are completely restructuring care programs to provide engaging, comprehensive health care support that will make a meaningful change in the lives of women and families. “
Boston-based startup PostEra received $ 24 million in Series A funding for its preclinical drug discovery machine learning technology. The round was led by the Clermont Group with the participation of Breyer Capital, Lifeforce Capital and I2BF Global Ventures as well as existing investors.
The new funds will help the company develop its medicinal chemistry platform, partner with other companies, and begin its own drug discovery.
“PostEra has made great strides in demonstrating the real utility of our AI-first medicinal chemistry platform to accelerate small molecule drug discovery.” Aaron Morris, CEO of PostEra, said in a statement.“We have a proven track record of using our machine learning technology to unify the design-make-test cycle of medicinal chemistry and greatly improve traditional trial and error approaches.”
Seniors-focused insurtech company The Helper Bees announced a $ 12.8 million Series B funding round. Trust Ventures led the round, in which Silverton Partners, Northwestern Mutual Fund Ventures, Impact Engine and Congress Avenue Ventures participated.
The company is focused on helping seniors age. The company works with an individual’s insurance company to provide data analytics, technology-enabled services, and streamline insurance claims.
Ianacare, a Boston-based startup focused on helping caregivers, has raised $ 12.1 million in funding, according to Series A TechCrunch.
The service enables caregivers to form social circles of friends and family members to help with daily chores. It helps to connect users with benefits and local resources, and Alsooffers coaching.
GrayMatters Health, a digital self-neuromodulation therapy company, announced a $ 10 million Series A funding round. Otsuka Medical Devices led the financing round.
The Israeli company focuses on the treatment of mental illness. It uses EKG and fMRI data to create a person’s EEP (Electrical Fingerprint) biomarker. The system includes an EEG neurofeedback device that it says can help regulate a patient’s EFP biomarker Website.
“GrayMatters introduces the first digital therapeutic device that directly targets and regulates specific brain biomarkers associated with mental disorders, while digitizing existing therapies focuses on alleviating the resulting symptoms and behaviors,” said Oded Kraft, Co-Founder and CEO by GrayMatters Health.
“This round of funding will help GrayMatters Health complete its clinical investigation, obtain regulatory approval, and kick off Prism for PTSD in the United States. It also supports our collaboration with McLean Hospital, the largest psychiatric affiliate of Harvard Medical School and a member of Mass General Brigham. Together we plan to conduct a clinical trial to determine the efficacy and safety of Prism as an add-on treatment for major depression (MDD) with anhedonia. “
CRIO digital clinical trial platform received $ 9 million in Series B funding. Abbhi Capital led the round in which Rally Ventures and NXT Ventures participated. This new round of investments brings the company’s total revenue to $ 15.7 million.
The new cash injection will be used to expand the product, engineering and business development teams. The Boston-based company works with a variety of healthcare stakeholders to streamline government workflows and collect clinical data.
